雅各臣科研制药(02633.HK)拟与建丰设合资开发肠胃科及呼吸系统科药物
格隆汇10月31日丨雅各臣科研制药(02633.HK)发布公告，公司全资附属公司Smiley Sun Limited与建丰胃仙-U有限公司于2019年10月31日订立合资公司协议。根据合资公司协议，将注册成立一间新公司，分别由Smiley及建丰持有50%权益，据此，双方将开发及开拓雅各臣科研制药集团及建丰旗下肠胃科及呼吸系统科药物以及食品╱健康补充品市场。
合资公司的业务将为：分销及销售订约双方若干产品至新市场，该等产品包括建丰产品及雅各臣科研制药集团产品；发掘及开发该等产品的有关产品╱产品线拓展；及于全球市场发掘及进行有关供应及分销非处方药物以及肠胃科及呼吸系统科类别的食品╱健康补充品业务。尤其是相对于Smiley及建丰而言，合资公司将有权优先收购肠胃科及呼吸系统科药物以及食品╱健康补充品品牌。
据悉，建丰于1960年代在香港注册成立，主要从事开发肠胃科及呼吸系统科药物业务。建丰为胃仙-U的品牌拥有人及于中国、香港及澳门的独家代理。胃仙-U为备受非处方市场认可的肠胃药，近60年来于中国、香港及澳门广受欢迎，广泛用于帮助消化以及舒缓因消化不良、胃痛、胃灼热、食欲不振及胸口作闷引起的不适。
自2019年1月起，公司全资制药附属公司正美药品有限公司已成为建丰胃仙-U的合约制造商，该公司的生产厂房已获国际医药品稽查协约组织(PIC/S)的良好制造规范(GMP)认证。呼佳喷雾剂为鼻用喷雾的畅销品牌。呼佳喷雾剂用于减轻因鼻敏感及╱或鼻道狭窄引致的不适症状，如因一般感冒病毒、花粉或室内尘埃引致的鼻黏膜红肿或充血。
公司称，凭借建立具备强大商业实力的区域市场平台，加上雅各臣科研制药集团成功伙伴关系的优秀往绩，雅各臣科研制药集团正处于优越位置，与知名合作伙伴进行战略合作，通过授权、技术转让或产品代理，从亚太区及大中华地区的高增长市场潜力中受惠。建丰长久以来为药剂业界知名翘楚，故董事会认为成立合资公司不仅会缔造订约方之间的协同效应，亦为雅各臣科研制药集团于开拓地区市场时，并拓展其肠胃科及呼吸系统科药物以及食物╱健康补充品组合策略上建立重要一环。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
